{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:09:32Z","timestamp":1787497772554,"version":"build-2736575974"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006506","name":"Minist\u00e9rio da Sa\u00fade","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006506","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.vhri.2025.101088","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T16:46:11Z","timestamp":1740415571000},"page":"101088","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Matching-Adjusted Indirect Comparison Studies in Oncology: A Scoping Review Focused on Reporting Quality"],"prefix":"10.1016","volume":"47","author":[{"given":"Cec\u00edlia Menezes","family":"Farinasso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vin\u00edcius Lins","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fl\u00e1via Cordeiro","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline Pereira","family":"da Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia do Carmo Silva","family":"Parreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layssa Andrade","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lays Pires","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Camila","family":"Lucchetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Haliton Alves","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vhri.2025.101088_bib1","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","article-title":"Chapter 11: Undertaking network meta-analyses","author":"Chaimani","year":"2023"},{"issue":"5","key":"10.1016\/j.vhri.2025.101088_bib2","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jval.2019.01.001","article-title":"Health technology assessment challenges in oncology: 20 years of value in health","volume":"22","author":"Kim","year":"2019","journal-title":"Value Health"},{"issue":"47","key":"10.1016\/j.vhri.2025.101088_bib3","first-page":"803","article-title":"Indirect comparisons and network meta-analyses","volume":"112","author":"Kiefer","year":"2015","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"10.1016\/j.vhri.2025.101088_bib4","author":"Phillippo"},{"issue":"10","key":"10.1016\/j.vhri.2025.101088_bib5","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","article-title":"Comparative effectiveness without head-to-head trials","volume":"28","author":"Signorovitch","year":"2010","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.vhri.2025.101088_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40164-022-00268-z","article-title":"Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel","volume":"11","author":"Cartron","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.vhri.2025.101088_bib7","author":"Posadzki"},{"issue":"4","key":"10.1016\/j.vhri.2025.101088_bib8","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/jrsm.1372","article-title":"Assessing the impact of a matching-adjusted indirect comparison in a Bayesian network meta-analysis","volume":"10","author":"Leahy","year":"2019","journal-title":"Res Synth Methods"},{"issue":"1","key":"10.1016\/j.vhri.2025.101088_bib9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12874-020-01124-6","article-title":"Performance of unanchored matching-adjusted indirect comparison (MAIC) for the evidence synthesis of single-arm trials with time-to-event outcomes","volume":"20","author":"Jiang","year":"2020","journal-title":"BMC Med Res Methodol"},{"issue":"9","key":"10.1016\/j.vhri.2025.101088_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2017.08.1785","article-title":"Acceptance of population-adjusted indirect treatment comparison methods in nice assessments","volume":"20","author":"Ivanescu","year":"2017","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.vhri.2025.101088_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"Arksey","year":"2005","journal-title":"Int J Soc Res Methodol"},{"key":"10.1016\/j.vhri.2025.101088_bib12","series-title":"Scoping reviews","author":"Peters","year":"2024"},{"issue":"7","key":"10.1016\/j.vhri.2025.101088_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-072156","article-title":"Mapping the characteristics, concepts and methodologies of matching-adjusted indirect comparison studies assessing pharmacological therapies in oncology: a scoping review protocol","volume":"13","author":"Farinasso","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.vhri.2025.101088_bib14","author":"Farinasso"},{"issue":"7","key":"10.1016\/j.vhri.2025.101088_bib15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.vhri.2025.101088_bib16","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile App for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.vhri.2025.101088_bib17","article-title":"Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC","volume":"10","author":"Chen","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.vhri.2025.101088_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1113346","article-title":"The cost-effectiveness analysis of serplulimab versus regorafenib for treating previously treated unresectable or metastatic microsatellite instability-high or deficient mismatch repair colorectal cancer in China","volume":"13","author":"Ma","year":"2023","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.vhri.2025.101088_bib19","first-page":"1137","article-title":"Belantamab mafodotin for the treatment of relapsed\/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis","volume":"14","author":"Nikolaou","year":"2021","journal-title":"J\u00a0Comp Eff Res"},{"issue":"8","key":"10.1016\/j.vhri.2025.101088_bib20","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s40273-021-01015-8","article-title":"The cost-effectiveness of lorlatinib versus chemotherapy as a second- or third-line treatment in anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer in Sweden","volume":"39","author":"Nilsson","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"10.1016\/j.vhri.2025.101088_bib21","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/j.clinthera.2017.08.010","article-title":"Cost-effectiveness of pomalidomide, carfilzomib, and daratumumab for the treatment of patients with heavily pretreated relapsed-refractory multiple myeloma in the United States","volume":"39","author":"Pelligra","year":"2017","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.vhri.2025.101088_bib22","first-page":"618","article-title":"Cost-effectiveness analysis of sintilimab\u00a0+ chemotherapy versus camrelizumab\u00a0+ chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China","volume":"25","author":"Rui","year":"2022","journal-title":"J\u00a0Med Econ"},{"issue":"6","key":"10.1016\/j.vhri.2025.101088_bib23","first-page":"577","article-title":"Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States","volume":"21","author":"Zhou","year":"2018","journal-title":"J\u00a0Med Econ"},{"issue":"1","key":"10.1016\/j.vhri.2025.101088_bib24","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1186\/s12913-024-11142-5","article-title":"Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.vhri.2025.101088_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2024.1333487","article-title":"The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China","volume":"12","author":"Dai","year":"2024","journal-title":"Front Public Health"},{"issue":"1","key":"10.1016\/j.vhri.2025.101088_bib26","first-page":"1108","article-title":"Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective","volume":"26","author":"Dhanji","year":"2023","journal-title":"J\u00a0Med Econ"},{"issue":"7","key":"10.1016\/j.vhri.2025.101088_bib27","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s12325-018-0734-9","article-title":"Comparative efficacy of treatments for previously treated advanced or metastatic non-small-cell lung cancer: a network meta-analysis","volume":"35","author":"Li","year":"2018","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.vhri.2025.101088_bib28","first-page":"191","article-title":"Comparison of treatments for nonmetastatic castration-resistant prostate cancer: matching-adjusted indirect comparison and network meta-analysis","volume":"114","author":"Wang","year":"2022"},{"issue":"10","key":"10.1016\/j.vhri.2025.101088_bib29","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2217\/cer-2018-0020","article-title":"Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison","volume":"7","author":"Ishak","year":"2018","journal-title":"J\u00a0Comp Eff Res"},{"issue":"1","key":"10.1016\/j.vhri.2025.101088_bib30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/2162-3619-2-32","article-title":"Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison","volume":"2","author":"Signorovitch","year":"2013","journal-title":"Exp Hematol Oncol"},{"issue":"9","key":"10.1016\/j.vhri.2025.101088_bib31","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1080\/03007995.2022.2100653","article-title":"Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L","volume":"38","author":"Reckamp","year":"2022","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"10.1016\/j.vhri.2025.101088_bib32","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1007\/s12325-020-01378-y","article-title":"Comparative efficacy of cabozantinib and regorafenib for advanced hepatocellular carcinoma","volume":"37","author":"Kelley","year":"2020","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.vhri.2025.101088_bib33","first-page":"691A","article-title":"Comparative efficacy of cabozantinib and ramucirumab after sorafenib for patients with advanced hepatocellular carcinoma and AFP \u2265 400 ng\/ml","volume":"72","author":"Trojan","year":"2020","journal-title":"Hepatology"},{"issue":"20","key":"10.1016\/j.vhri.2025.101088_bib34","first-page":"2499","article-title":"Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-","volume":"18","author":"Reckamp","year":"2022","journal-title":"cell lung cancer"},{"issue":"4","key":"10.1016\/j.vhri.2025.101088_bib35","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1007\/s12325-019-0873-7","article-title":"Matching-Adjusted Indirect Comparison of Blinatumomab vs. inotuzumab ozogamicin for Adults with Relapsed\/Refractory Acute lymphoblastic leukemia","volume":"36","author":"Song","year":"2019","journal-title":"Adv Ther"},{"issue":"10","key":"10.1016\/j.vhri.2025.101088_bib36","first-page":"2342","article-title":"Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-na\u00efve chronic lymphocytic leukemia","volume":"62","author":"Davids","year":"2021"},{"key":"10.1016\/j.vhri.2025.101088_bib37","article-title":"Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer","volume":"13","author":"Hettle","year":"2021","journal-title":"J\u00a0Comp Eff Res"},{"issue":"1","key":"10.1016\/j.vhri.2025.101088_bib38","first-page":"140","article-title":"Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma","volume":"14","author":"Maloney","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.vhri.2025.101088_bib39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"10.1016\/j.vhri.2025.101088_bib40","first-page":"2472","article-title":"Comparative efficacy of cabozantinib and ramucirumab after sorafenib for patients with hepatocellular carcinoma and alpha-fetoprotein \u2265 400 ng\/mL: a matching-adjusted indirect comparison","volume":"38","author":"Trojan","year":"2021"},{"issue":"6","key":"10.1016\/j.vhri.2025.101088_bib41","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1185\/03007995.2011.576238","article-title":"Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials","volume":"27","author":"Signorovitch","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.vhri.2025.101088_bib42","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1185\/03007995.2014.977992","article-title":"One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison","volume":"31","author":"Signorovitch","year":"2015","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.vhri.2025.101088_bib43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2217\/cer-2021-0221","article-title":"Palbociclib versus abemaciclib in HR+\/HER2- advanced breast cancer: an indirect comparison of patient-reported end points","volume":"11","author":"Law","year":"2022","journal-title":"J\u00a0Comp Eff Res"},{"issue":"5","key":"10.1016\/j.vhri.2025.101088_bib44","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s12325-022-02099-0","article-title":"Transarterial radioembolization versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: a matching-adjusted indirect comparison of time to deterioration in quality of life","volume":"39","author":"Agirrezabal","year":"2022","journal-title":"Adv Ther"},{"issue":"7","key":"10.1016\/j.vhri.2025.101088_bib45","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.cllc.2024.08.003","article-title":"Comparative efficacy and safety of lorlatinib versus alectinib and lorlatinib versus brigatinib for ALK-positive advanced\/metastatic NSCLC: matching-adjusted indirect comparisons","volume":"25","author":"Garcia","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.vhri.2025.101088_bib46","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231216095","article-title":"Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+\/HER2- advanced breast cancer","volume":"15","author":"Jhaveri","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"10.1016\/j.vhri.2025.101088_bib47","doi-asserted-by":"crossref","first-page":"100510","DOI":"10.1016\/j.esmoop.2022.100510","article-title":"Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer","volume":"7","author":"Tombal","year":"2022","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.vhri.2025.101088_bib48","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.euo.2023.01.012","article-title":"A\u00a0matching-adjusted indirect comparison of nivolumab plus cabozantinib versus pembrolizumab plus axitinib in patients with advanced renal cell carcinoma","volume":"6","author":"McGregor","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"12","key":"10.1016\/j.vhri.2025.101088_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12123648","article-title":"A\u00a0matching-adjusted indirect comparison of pembrolizumab\u00a0+ chemotherapy vs nivolumab\u00a0+ ipilimumab as first-line therapies in patients with PD-L1 TPS \u22651% metastatic NSCLC","volume":"12","author":"Halmos","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.vhri.2025.101088_bib50","first-page":"295","article-title":"Indirect comparison of pembrolizumab monotherapy versus nivolumab\u00a0+ ipilimumab in first-line metastatic lung cancer","volume":"14","author":"Halmos","year":"2022"},{"key":"10.1016\/j.vhri.2025.101088_bib51","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2147\/CMAR.S163478","article-title":"Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2- advanced breast cancer","volume":"10","author":"Tremblay","year":"2018","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1016\/j.vhri.2025.101088_bib52","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s12325-021-01885-6","article-title":"Apalutamide compared with darolutamide for the treatment of non-metastatic castration-resistant prostate cancer: efficacy and tolerability in a matching-adjusted indirect comparison","volume":"39","author":"Chowdhury","year":"2022","journal-title":"Adv Ther"},{"issue":"12","key":"10.1016\/j.vhri.2025.101088_bib53","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/ajh.25963","article-title":"Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: efficacy in transplant-ineligible untreated myeloma","volume":"95","author":"Durie","year":"2020","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.vhri.2025.101088_bib54","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2217\/cer-2020-0272","article-title":"Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive\/HER2-negative advanced breast cancer","volume":"10","author":"Rugo","year":"2022","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.vhri.2025.101088_bib55","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1007\/s12325-017-0564-1","article-title":"Comparative efficacy of ibrutinib versus obinutuzumab\u00a0+ chlorambucil in first-line treatment of chronic lymphocytic leukemia: a matching-adjusted indirect comparison","volume":"34","author":"Van Sanden","year":"2017","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.vhri.2025.101088_bib56","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s12325-019-01157-4","article-title":"Matching-adjusted indirect comparison of health-related quality of life and adverse events of apalutamide versus enzalutamide in non-metastatic castration-resistant prostate cancer","volume":"37","author":"Chowdhury","year":"2020","journal-title":"Adv Ther"},{"issue":"8","key":"10.1016\/j.vhri.2025.101088_bib57","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s12325-019-00991-w","article-title":"Indirect treatment comparison of inotuzumab ozogamicin versus blinatumomab for relapsed or refractory acute lymphoblastic leukemia","volume":"36","author":"Proskorovsky","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.vhri.2025.101088_bib58","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231152843","article-title":"Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+\/HER2- advanced breast cancer: a matching-adjusted indirect comparison","volume":"15","author":"Rugo","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.vhri.2025.101088_bib59","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s12325-019-01156-5","article-title":"Matching-adjusted indirect comparison of the efficacy of apalutamide and enzalutamide with ADT in the treatment of non-metastatic castration-resistant prostate cancer","volume":"37","author":"Chowdhury","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.vhri.2025.101088_bib60","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1007\/s12325-022-02245-8","article-title":"The hospitalization-related costs of adverse events for novel androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer: an indirect comparison","volume":"39","author":"Shore","year":"2022","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.vhri.2025.101088_bib61","doi-asserted-by":"crossref","first-page":"49","DOI":"10.36469\/jheor.2024.120954","article-title":"Matching-adjusted indirect comparison of the efficacy and safety of erdafitinib vs enfortumab vedotin in patients with locally advanced metastatic urothelial carcinoma","volume":"11","author":"Van Sanden","year":"2024","journal-title":"J\u00a0Health Econ Outcomes Res"},{"issue":"2","key":"10.1016\/j.vhri.2025.101088_bib62","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2217\/cer-2021-0221","article-title":"Palbociclib versus abemaciclib in HR+\/HER2- advanced breast cancer: an indirect comparison of patient-reported end points","volume":"11","author":"Aziez","year":"2022","journal-title":"J\u00a0Comp Eff Res"},{"issue":"6","key":"10.1016\/j.vhri.2025.101088_bib63","first-page":"2668","article-title":"Tafasitamab plus lenalidomide versus 3 rituximab-based treatments for non-transplant eligible relapsed\/refractory diffuse large B-cell lymphoma: a matching-adjusted indirect comparison","volume":"39","author":"Tanaka","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.vhri.2025.101088_bib64","first-page":"714","volume":"61","author":"Szeto","year":"2020","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.vhri.2025.101088_bib65","first-page":"e738","article-title":"Matching-adjusted indirect comparison of the efficacy of Loncastuximab Tesirine versus treatment in the chemoimmunotherapy era for relapsed\/refractory diffuse large B-cell lymphoma","volume":"22","author":"Hamadani","year":"2022","journal-title":"Eur J Rheumatol"},{"issue":"2","key":"10.1016\/j.vhri.2025.101088_bib66","first-page":"143","article-title":"Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison","volume":"13","author":"Moreau","year":"2021"},{"key":"10.1016\/j.vhri.2025.101088_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2023.09.004","article-title":"A\u00a0methodological review of population-adjusted indirect comparisons reveals inconsistent reporting and suggests publication bias","volume":"163","author":"Serret-Larmande","year":"2023","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"5","key":"10.1016\/j.vhri.2025.101088_bib75","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/jrsm.1653","article-title":"Population adjusted-indirect comparisons in health technology assessment: a methodological systematic review","volume":"14","author":"Truong","year":"2023","journal-title":"Res Synth Methods"},{"issue":"7","key":"10.1016\/j.vhri.2025.101088_bib76","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1007\/s12325-023-02520-2","article-title":"A\u00a0critical appraisal of matching-adjusted indirect comparisons in spinal muscular atrophy","volume":"40","author":"Jiang","year":"2023","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.vhri.2025.101088_bib67","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13643-022-02071-7","article-title":"Guidance on review type selection for health technology assessments: key factors and considerations for deciding when to conduct a de novo systematic review, an update of a systematic review, or an overview of systematic reviews","volume":"11","author":"Kim","year":"2022","journal-title":"Syst Rev"},{"issue":"32","key":"10.1016\/j.vhri.2025.101088_bib68","doi-asserted-by":"crossref","first-page":"E901","DOI":"10.1503\/cmaj.200077","article-title":"Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses","volume":"192","author":"Schandelmaier","year":"2020","journal-title":"Can Med Assoc J"},{"issue":"30","key":"10.1016\/j.vhri.2025.101088_bib69","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1002\/sim.8759","article-title":"Assessing the performance of population adjustment methods for anchored indirect comparisons: a simulation study","volume":"39","author":"Phillippo","year":"2020","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.vhri.2025.101088_bib70","first-page":"55","article-title":"Matching-Adjusted Indirect Comparisons in the assessment of hemato-oncological drugs","volume":"45","author":"Mart\u00ednez-Sesmero","year":"2021","journal-title":"Farm Hosp"},{"issue":"17","key":"10.1016\/j.vhri.2025.101088_bib71","article-title":"MSR74 the use of matching-adjusted indirect comparison for oncology submissions in NICE","volume":"26","author":"Kaur","year":"2023","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.vhri.2025.101088_bib73","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/jrsm.1709","article-title":"A\u00a0comprehensive review and shiny application on the matching-adjusted indirect comparison","volume":"15","author":"Jiang","year":"2024","journal-title":"Res Synth Methods"},{"issue":"4","key":"10.1016\/j.vhri.2025.101088_bib74","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1136\/bmjebm-2022-112126","article-title":"Open access journal publication in health and medical research and open science: benefits, challenges and limitations","volume":"29","author":"Logullo","year":"2024","journal-title":"BMJ Evid based Med"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109925000135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109925000135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:05:50Z","timestamp":1745971550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109925000135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":76,"alternative-id":["S2212109925000135"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2025.101088","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Matching-Adjusted Indirect Comparison Studies in Oncology: A Scoping Review Focused on Reporting Quality","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2025.101088","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101088"}}